Sentiment-Signal
9,2
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
19.2
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (09.03.2026)
HOCH Abgang Schlüsselpersonen (09.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 12.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 29.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
| 14.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
Stammdaten
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Unternehmen & Branche
| Name | IONIS PHARMACEUTICALS INC |
|---|---|
| Ticker | IONS |
| CIK | 0000874015 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 462222100 |
|---|---|
| ISIN | US4622221004 |
| Typ | Common Stock |
| Marktkapitalisierung | 12,39 Mrd. USD |
| Beta | 0,40 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 203,330,000 | -229,394,000 | -1.41 | 3,523,836,000 | 489,089,000 |
| 2025-09-30 | 10-Q | 156,719,000 | -128,606,000 | -0.80 | 3,033,091,000 | 617,967,000 |
| 2025-06-30 | 10-Q | 452,049,000 | 123,551,000 | 0.70 | 2,985,133,000 | 631,724,000 |
| 2025-03-31 | 10-Q | 131,612,000 | -146,938,000 | -0.93 | 2,812,948,000 | 475,726,000 |
| 2024-12-31 | 10-K | 226,577,000 | -104,349,000 | -0.66 | 3,003,675,000 | 588,351,000 |
| 2024-09-30 | 10-Q | 133,814,000 | -140,480,000 | -0.95 | 3,081,099,000 | 662,468,000 |
| 2024-06-30 | 10-Q | 225,250,000 | -66,265,000 | -0.45 | 2,691,128,000 | 263,698,000 |
| 2024-03-31 | 10-Q | 119,497,000 | -142,803,000 | -0.98 | 2,763,928,000 | 296,515,000 |
| 2023-12-31 | 10-K | 324,505,000 | -9,263,000 | -0.06 | 2,990,072,000 | 386,686,000 |
| 2023-09-30 | 10-Q | 144,207,000 | -147,410,000 | -1.03 | 2,933,971,000 | 315,460,000 |
| 2023-06-30 | 10-Q | 188,411,000 | -85,290,000 | -0.60 | 2,971,131,000 | 428,301,000 |
| 2023-03-31 | 10-Q | 130,524,000 | -124,323,000 | -0.87 | 2,885,221,000 | 486,570,000 |
| 2022-12-31 | 10-K | 151,890,000 | -52,430,000 | -0.37 | 2,533,876,000 | 572,887,000 |
| 2022-09-30 | 10-Q | 159,767,000 | -46,992,000 | -0.33 | 2,421,971,000 | 594,361,000 |
| 2022-06-30 | 10-Q | 133,791,000 | -105,135,000 | -0.74 | 2,456,133,000 | 624,726,000 |
| 2022-03-31 | 10-Q | 141,919,000 | -65,165,000 | -0.46 | 2,519,092,000 | 709,574,000 |
| 2021-12-31 | 10-K | 440,006,000 | 224,613,000 | 1.41 | 2,611,690,000 | 771,737,000 |
| 2021-09-30 | 10-Q | 133,093,000 | -82,466,000 | -0.58 | 2,414,893,000 | 530,536,000 |
| 2021-06-30 | 10-Q | 125,750,000 | -80,875,000 | -0.57 | 2,497,069,000 | 582,674,000 |
| 2021-03-31 | 10-Q | 111,607,000 | -89,869,000 | -0.64 | 2,248,551,000 | 680,564,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| FMR LLC | 35,800,101 | 0 | 35,800,101 | 1,921,936,969 | Neu | +100,0% | |
| Capital World Investors | 17,961,299 | 0 | 17,961,299 | 1,420,918,364 | Neu | +100,0% | |
| VANGUARD GROUP INC | 16,440,459 | 0 | 16,440,459 | 1,300,604,712 | Neu | +100,0% | |
| BlackRock, Inc. | 35,954,863 | 0 | 35,954,863 | 880,813,813 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 24,753,325 | 0 | 24,753,325 | 524,650,318 | Neu | +100,0% | |
| STATE STREET CORP | 29,469,865 | 0 | 29,469,865 | 352,034,127 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 52,908,646 | 0 | 52,908,646 | 285,771,560 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 3,148,849 | 0 | 3,148,849 | 249,157,703 | Neu | +100,0% | |
| Tweedy, Browne Co LLC | 2,464,930 | 0 | 2,464,930 | 195,000,612 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 3,415,792 | 0 | 3,415,792 | 184,098,769 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 2,313,036 | 0 | 2,313,036 | 182,984,278 | Neu | +100,0% | |
| VOYA INVESTMENT MANAGEMENT LLC | 95,958,760 | 0 | 95,958,760 | 158,488,868 | Neu | +100,0% | |
| BAKER BROS. ADVISORS LP | 1,791,841 | 0 | 1,791,841 | 141,752,542 | Neu | +100,0% | |
| Deep Track Capital, LP | 1,700,000 | 0 | 1,700,000 | 134,487,000 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 1,617,106 | 0 | 1,617,106 | 127,929,439 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,541,841 | 0 | 1,541,841 | 121,975,042 | Neu | +100,0% | |
| CAPSTONE INVESTMENT ADVISORS, LLC | 84,949,000 | 0 | 84,949,000 | 116,698,689 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 1,418,491 | 0 | 1,418,491 | 112,476,314 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,388,567 | 0 | 1,388,567 | 109,849,535 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 7,879,997 | 0 | 7,879,997 | 104,814,000 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 1,321,345 | 0 | 1,321,345 | 104,531,581 | Neu | +100,0% | |
| Invesco Ltd. | 2,769,290 | 0 | 2,769,290 | 102,795,982 | Neu | +100,0% | |
| BARCLAYS PLC | 2,731,371 | 0 | 2,731,371 | 91,105,071 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 3,072,466 | 0 | 3,072,466 | 87,864,342 | Neu | +100,0% | |
| Connor, Clark & Lunn Investment Management Ltd. | 1,076,370 | 0 | 1,076,370 | 85,151,631 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,063,327 | 0 | 1,063,327 | 84,119,799 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 15,154,579 | 0 | 15,154,579 | 83,339,124 | Neu | +100,0% | |
| UBS Group AG | 1,045,041 | 0 | 1,045,041 | 82,673,193 | Neu | +100,0% | |
| MORGAN STANLEY | 1,193,906 | 0 | 1,193,906 | 80,943,791 | Neu | +100,0% | |
| CAMDEN ASSET MANAGEMENT L P /CA | 48,066,000 | 0 | 48,066,000 | 76,343,228 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 848,104 | 0 | 848,104 | 67,093,507 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 846,718 | 0 | 846,718 | 66,983,861 | Neu | +100,0% | |
| CSS LLC/IL | 48,221,000 | 0 | 48,221,000 | 66,965,399 | Neu | +100,0% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 812,747 | 0 | 812,747 | 64,296,415 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 37,293,262 | 0 | 37,293,262 | 61,810,443 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 25,832,803 | 0 | 25,832,803 | 61,352,726 | Neu | +100,0% | |
| GROUPAMA ASSET MANAGMENT | 766,889 | 0 | 766,889 | 60,668,589 | Neu | +100,0% | |
| Candriam S.C.A. | 677,629 | 0 | 677,629 | 53,609,512 | Neu | +100,0% | |
| Ovata Capital Management Ltd | 37,723,000 | 0 | 37,723,000 | 51,860,826 | Neu | +100,0% | |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 35,050,000 | 0 | 35,050,000 | 50,483,075 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 598,748 | 0 | 598,748 | 47,366,953 | Neu | +100,0% | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 584,970 | 0 | 584,970 | 46,276,977 | Neu | +100,0% | |
| LMR Partners LLP | 27,335,000 | 0 | 27,335,000 | 46,073,475 | Neu | +100,0% | |
| Tri Locum Partners LP | 557,174 | 0 | 557,174 | 44,078,035 | Neu | +100,0% | |
| DLD Asset Management, LP | 26,512,400 | 0 | 26,512,400 | 43,289,073 | Neu | +100,0% | |
| Eversept Partners, LP | 538,218 | 0 | 538,218 | 42,578,426 | Neu | +100,0% | |
| Shaolin Capital Management LLC | 27,500,000 | 0 | 27,500,000 | 37,701,505 | Neu | +100,0% | |
| Hudson Bay Capital Management LP | 475,000 | 0 | 475,000 | 37,577,250 | Neu | +100,0% | |
| PINNACLE ASSOCIATES LTD | 461,968 | 0 | 461,968 | 36,546,288 | Neu | +100,0% | |
| Squarepoint Ops LLC | 442,879 | 0 | 442,879 | 35,036,158 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -5,619 | 74.56 | -418,952.64 | -40,7% | |
| 2026-04-16 | Jenne Kyle | Officer, EVP, Chf GL Pdt Str Ofcr | Open Market Sale | -4,902 | 75.17 | -368,488.24 | -35,8% | |
| 2026-04-16 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -973 | 75.04 | -73,015.87 | -7,1% | |
| 2026-04-15 | PARSHALL B LYNNE | Director | Open Market Sale | -534 | 76.97 | -41,101.98 | -4,0% | |
| 2026-04-15 | PARSHALL B LYNNE | Director | Open Market Sale | -4,466 | 76.19 | -340,264.54 | -33,1% | |
| 2026-04-02 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -6,193 | 74.05 | -458,613.33 | -44,6% | |
| 2026-04-01 | KLEIN JOSEPH III | Director | Open Market Sale | -2,216 | 75.95 | -168,314.06 | -16,4% | |
| 2026-04-01 | KLEIN JOSEPH III | Director | Open Market Sale | -20,105 | 75.50 | -1,517,987.82 | -147,5% | |
| 2026-03-19 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -5,812 | 70.97 | -412,486.36 | -40,1% | |
| 2026-03-17 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -10,172 | 73.21 | -744,661.60 | -72,4% | |
| 2026-03-16 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -9,440 | 72.77 | -686,901.60 | -66,8% | |
| 2026-03-16 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -205,608 | 72.38 | -14,882,112.65 | -1446,5% | |
| 2026-03-10 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -17,591 | 76.34 | -1,342,909.25 | -130,5% | |
| 2026-03-10 | Jenne Kyle | Officer, EVP, Chf GL Pdt Str Ofcr | Open Market Sale | -21,191 | 75.50 | -1,599,962.88 | -155,5% | |
| 2026-03-10 | Jenne Kyle | Officer, EVP, Chf GL Pdt Str Ofcr | Open Market Sale | -16,086 | 76.30 | -1,227,361.80 | -119,3% | |
| 2026-03-10 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -16,512 | 75.47 | -1,246,234.94 | -121,1% | |
| 2026-03-09 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -1,684 | 75.58 | -127,281.77 | -12,4% | |
| 2026-03-09 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -117,604 | 75.26 | -8,850,641.83 | -860,2% | |
| 2026-03-09 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -7,382 | 74.11 | -547,087.40 | -53,2% | |
| 2026-03-09 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -10,148 | 75.25 | -763,662.37 | -74,2% | |
| 2026-03-04 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -201 | 80.00 | -16,080.00 | -1,6% | |
| 2026-03-04 | LOSCALZO JOSEPH | Director | Open Market Sale | -200 | 80.00 | -16,000.00 | -1,6% | |
| 2026-03-04 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -238 | 80.00 | -19,040.00 | -1,9% | |
| 2026-03-03 | KLEIN JOSEPH III | Director | Open Market Sale | -1,012 | 80.82 | -81,787.82 | -7,9% | |
| 2026-03-03 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -14,321 | 79.12 | -1,133,005.92 | -110,1% | |
| 2026-03-03 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -5,030 | 80.00 | -402,394.97 | -39,1% | |
| 2026-03-03 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -755 | 80.84 | -61,031.94 | -5,9% | |
| 2026-03-03 | LOSCALZO JOSEPH | Director | Open Market Sale | -832 | 80.33 | -66,832.81 | -6,5% | |
| 2026-03-03 | Diaz Allene M. | Director | Open Market Sale | -39,265 | 79.11 | -3,106,411.21 | -301,9% | |
| 2026-03-03 | Diaz Allene M. | Director | Open Market Sale | -14,608 | 79.88 | -1,166,814.00 | -113,4% | |
| 2026-03-03 | Diaz Allene M. | Director | Open Market Sale | -1,005 | 80.80 | -81,203.00 | -7,9% | |
| 2026-03-03 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -4,096 | 79.36 | -325,058.56 | -31,6% | |
| 2026-03-03 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -2,088 | 80.41 | -167,891.70 | -16,3% | |
| 2026-03-03 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -36 | 81.01 | -2,916.36 | -0,3% | |
| 2026-03-03 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -71,600 | 79.10 | -5,663,488.40 | -550,5% | |
| 2026-03-03 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -12,687 | 79.88 | -1,013,409.65 | -98,5% | |
| 2026-03-03 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -802 | 80.76 | -64,771.12 | -6,3% | |
| 2026-03-03 | KLEIN JOSEPH III | Director | Open Market Sale | -13,526 | 79.17 | -1,070,907.52 | -104,1% | |
| 2026-03-03 | KLEIN JOSEPH III | Director | Open Market Sale | -6,794 | 80.00 | -543,486.03 | -52,8% | |
| 2026-02-13 | Swayze Eric | Officer, EVP Research | Open Market Sale | -9,435 | 81.56 | -769,511.05 | -74,8% | |
| 2026-02-13 | Swayze Eric | Officer, EVP Research | Open Market Sale | -6,207 | 82.07 | -509,402.90 | -49,5% | |
| 2026-02-11 | PARSHALL B LYNNE | Director | Open Market Sale | -5,000 | 82.72 | -413,588.50 | -40,2% | |
| 2026-02-06 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -29,430 | 85.79 | -2,524,820.30 | -245,4% | |
| 2026-02-02 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -48,626 | 83.03 | -4,037,338.98 | -392,4% | |
| 2026-02-02 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -20,000 | 82.60 | -1,651,980.00 | -160,6% | |
| 2026-02-02 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -16,463 | 83.03 | -1,366,896.55 | -132,9% | |
| 2026-01-30 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -6,179 | 83.53 | -516,153.50 | -50,2% | |
| 2026-01-30 | Swayze Eric | Officer, EVP Research | Open Market Sale | -6,179 | 82.93 | -512,446.10 | -49,8% | |
| 2026-01-30 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -5,296 | 82.96 | -439,364.10 | -42,7% | |
| 2026-01-30 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -6,179 | 83.03 | -513,047.93 | -49,9% | |
| 2026-01-30 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -6,179 | 83.45 | -515,629.52 | -50,1% | |
| 2026-01-30 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -5,885 | 82.95 | -488,140.74 | -47,4% | |
| 2026-01-30 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -6,988 | 83.24 | -581,702.08 | -56,5% | |
| 2026-01-30 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -62,970 | 82.72 | -5,208,979.15 | -506,3% | |
| 2026-01-22 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -3,977 | 81.34 | -323,490.37 | -31,4% | |
| 2026-01-16 | Swayze Eric | Officer, EVP Research | Open Market Sale | -49 | 75.97 | -3,722.53 | -0,4% | |
| 2026-01-16 | Jenne Kyle | Officer, EVP, Chf GL Pdt Str Ofcr | Open Market Sale | -1,823 | 75.96 | -138,475.08 | -13,5% | |
| 2026-01-16 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -8,480 | 75.11 | -636,932.80 | -61,9% | |
| 2026-01-16 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -9,302 | 75.59 | -703,138.18 | -68,3% | |
| 2026-01-16 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -6,907 | 75.75 | -523,205.25 | -50,9% | |
| 2026-01-16 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -1,149 | 75.78 | -87,071.22 | -8,5% | |
| 2026-01-16 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -8,977 | 75.15 | -674,621.55 | -65,6% | |
| 2026-01-16 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -12,922 | 75.22 | -971,992.84 | -94,5% | |
| 2026-01-16 | Kordasiewicz Holly B. | Officer, EVP, Chief Development Officer | Open Market Sale | -4,141 | 75.66 | -313,308.06 | -30,5% | |
| 2026-01-16 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -44,034 | 74.82 | -3,294,623.88 | -320,2% | |
| 2026-01-16 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -9,191 | 75.84 | -697,045.44 | -67,7% | |
| 2026-01-16 | Swayze Eric | Officer, EVP Research | Open Market Sale | -9,884 | 75.34 | -744,660.56 | -72,4% | |
| 2026-01-16 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -8,353 | 75.95 | -634,410.35 | -61,7% | |
| 2026-01-07 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -3,460 | 84.62 | -292,785.20 | -28,5% | |
| 2026-01-07 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -25,545 | 85.36 | -2,180,521.20 | -211,9% | |
| 2026-01-07 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -9,264 | 84.62 | -783,919.68 | -76,2% | |
| 2026-01-07 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -3,829 | 84.62 | -324,009.98 | -31,5% | |
| 2026-01-07 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -2,101 | 85.36 | -179,341.36 | -17,4% | |
| 2026-01-02 | Swayze Eric | Officer, EVP Research | Open Market Sale | -18,338 | 79.27 | -1,453,653.26 | -141,3% | |
| 2026-01-02 | Swayze Eric | Officer, EVP Research | Open Market Sale | -5,125 | 78.57 | -402,671.25 | -39,1% | |
| 2025-12-01 | WENDER JOSEPH H | Director | Open Market Sale | -20,571 | 80.67 | -1,659,361.77 | -161,3% | |
| 2025-12-01 | WENDER JOSEPH H | Director | Open Market Sale | -7,429 | 81.23 | -603,485.90 | -58,7% | |
| 2025-11-25 | KLEIN JOSEPH III | Director | Open Market Sale | -4,000 | 80.00 | -320,000.00 | -31,1% | |
| 2025-11-25 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -16,777 | 80.91 | -1,357,442.17 | -131,9% | |
| 2025-11-19 | HERMAN JOAN E | Director | Open Market Sale | -12,000 | 72.13 | -865,590.00 | -84,1% | |
| 2025-11-19 | HERMAN JOAN E | Director | Open Market Sale | -32,000 | 72.13 | -2,308,240.00 | -224,4% | |
| 2025-11-06 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -8,000 | 76.17 | -609,379.20 | -59,2% | |
| 2025-11-06 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -18,300 | 75.42 | -1,380,204.30 | -134,1% | |
| 2025-11-06 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -14,738 | 76.10 | -1,121,520.53 | -109,0% | |
| 2025-11-05 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -800 | 75.01 | -60,008.00 | -5,8% | |
| 2025-11-05 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -801 | 75.01 | -60,083.01 | -5,8% | |
| 2025-11-03 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -775 | 75.05 | -58,166.85 | -5,7% | |
| 2025-11-03 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -905 | 75.05 | -67,923.87 | -6,6% | |
| 2025-11-03 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -775 | 75.05 | -58,166.85 | -5,7% | |
| 2025-11-03 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -905 | 75.05 | -67,923.87 | -6,6% | |
| 2025-10-31 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -20,000 | 75.11 | -1,502,166.00 | -146,0% | |
| 2025-10-31 | LOSCALZO JOSEPH | Director | Open Market Sale | -16,000 | 75.10 | -1,201,668.80 | -116,8% | |
| 2025-10-31 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -34,664 | 75.11 | -2,603,554.11 | -253,1% | |
| 2025-10-31 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -34,585 | 75.11 | -2,597,620.56 | -252,5% | |
| 2025-10-31 | WENDER JOSEPH H | Director | Open Market Sale | -11,200 | 75.16 | -841,776.32 | -81,8% | |
| 2025-10-30 | WENDER JOSEPH H | Director | Open Market Sale | -5,975 | 73.85 | -441,253.75 | -42,9% | |
| 2025-10-30 | WENDER JOSEPH H | Director | Open Market Sale | -8,341 | 73.16 | -610,227.56 | -59,3% | |
| 2025-10-30 | WENDER JOSEPH H | Director | Open Market Sale | -2,484 | 72.19 | -179,319.96 | -17,4% | |
| 2025-10-16 | Swayze Eric | Officer, EVP Research | Open Market Sale | -53 | 73.62 | -3,901.93 | -0,4% | |
| 2025-10-16 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -1,263 | 73.62 | -92,983.70 | -9,0% | |
| 2025-10-15 | PARSHALL B LYNNE | Director | Open Market Sale | -5,000 | 71.74 | -358,721.50 | -34,9% | |
| 2025-10-15 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -6,000 | 72.94 | -437,653.80 | -42,5% | |
| 2025-10-15 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -12,425 | 72.23 | -897,398.11 | -87,2% | |
| 2025-10-14 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -11,475 | 72.03 | -826,589.00 | -80,3% | |
| 2025-10-06 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -3,241 | 69.27 | -224,488.19 | -21,8% | |
| 2025-10-06 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -1,625 | 69.37 | -112,725.11 | -11,0% | |
| 2025-10-06 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -437 | 69.26 | -30,268.24 | -2,9% | |
| 2025-10-06 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -10,200 | 69.89 | -712,849.44 | -69,3% | |
| 2025-10-06 | Swayze Eric | Officer, EVP Research | Open Market Sale | -6,849 | 69.02 | -472,717.98 | -45,9% | |
| 2025-10-02 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -30,203 | 67.69 | -2,044,416.91 | -198,7% | |
| 2025-10-02 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -15,000 | 68.01 | -1,020,210.00 | -99,2% | |
| 2025-10-02 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -34,461 | 67.69 | -2,332,637.52 | -226,7% | |
| 2025-10-02 | Swayze Eric | Officer, EVP Research | Open Market Sale | -12,972 | 66.23 | -859,082.37 | -83,5% | |
| 2025-10-01 | Swayze Eric | Officer, EVP Research | Open Market Sale | -14,142 | 66.09 | -934,661.75 | -90,8% | |
| 2025-10-01 | WENDER JOSEPH H | Director | Open Market Sale | -16,800 | 65.50 | -1,100,384.88 | -107,0% | |
| 2025-09-30 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -57,900 | 65.24 | -3,777,668.13 | -367,2% | |
| 2025-09-30 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -49,800 | 65.26 | -3,249,733.86 | -315,9% | |
| 2025-09-30 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -14,827 | 64.68 | -958,976.26 | -93,2% | |
| 2025-09-29 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -10,473 | 64.54 | -675,945.22 | -65,7% | |
| 2025-09-12 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -1,700 | 64.58 | -109,787.19 | -10,7% | |
| 2025-09-09 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -11,950 | 62.16 | -742,838.29 | -72,2% | |
| 2025-09-09 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -20,000 | 64.56 | -1,291,106.00 | -125,5% | |
| 2025-09-09 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -1,000 | 64.56 | -64,555.30 | -6,3% | |
| 2025-09-05 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -250 | 62.00 | -15,500.00 | -1,5% | |
| 2025-09-05 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -6,000 | 59.60 | -357,580.80 | -34,8% | |
| 2025-09-03 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -127,500 | 60.13 | -7,667,046.75 | -745,2% | |
| 2025-09-03 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -59,699 | 61.06 | -3,645,394.07 | -354,3% | |
| 2025-09-03 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -16,615 | 59.12 | -982,262.19 | -95,5% | |
| 2025-09-03 | WENDER JOSEPH H | Director | Open Market Sale | -11,200 | 60.14 | -673,548.96 | -65,5% | |
| 2025-09-03 | KLEIN JOSEPH III | Director | Open Market Sale | -28,000 | 60.00 | -1,680,000.00 | -163,3% | |
| 2025-09-03 | KLEIN JOSEPH III | Director | Open Market Sale | -28,000 | 60.00 | -1,680,000.00 | -163,3% | |
| 2025-09-03 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -3,162 | 61.02 | -192,942.71 | -18,8% | |
| 2025-09-03 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -33,909 | 60.62 | -2,055,563.58 | -199,8% | |
| 2025-09-03 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -12,455 | 60.46 | -753,039.26 | -73,2% | |
| 2025-09-03 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -65,475 | 60.89 | -3,986,772.75 | -387,5% | |
| 2025-09-03 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -11,375 | 61.42 | -698,652.50 | -67,9% | |
| 2025-09-03 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -7,203 | 61.42 | -442,381.61 | -43,0% | |
| 2025-09-03 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -30,000 | 59.09 | -1,772,592.00 | -172,3% | |
| 2025-09-03 | WENDER JOSEPH H | Director | Open Market Sale | -11,200 | 60.14 | -673,548.96 | -65,5% | |
| 2025-09-03 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -2,800 | 62.01 | -173,628.28 | -16,9% | |
| 2025-09-03 | LOSCALZO JOSEPH | Director | Open Market Sale | -16,000 | 60.15 | -962,371.20 | -93,5% | |
| 2025-09-02 | Swayze Eric | Officer, EVP Research | Open Market Sale | -10,000 | 49.22 | -492,200.00 | -47,8% | |
| 2025-09-02 | PARSHALL B LYNNE | Director | Open Market Sale | -10,750 | 50.42 | -542,015.00 | -52,7% | |
| 2025-09-02 | PARSHALL B LYNNE | Director | Open Market Sale | -9,250 | 51.49 | -476,282.50 | -46,3% | |
| 2025-09-02 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -5,000 | 49.14 | -245,700.00 | -23,9% | |
| 2025-09-02 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -13,050 | 54.51 | -711,418.14 | -69,1% | |
| 2025-09-02 | WENDER JOSEPH H | Director | Open Market Sale | -11,200 | 55.04 | -616,432.32 | -59,9% | |
| 2025-09-02 | WENDER JOSEPH H | Director | Open Market Sale | -5,600 | 57.53 | -322,174.16 | -31,3% | |
| 2025-09-02 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -10,000 | 50.37 | -503,671.00 | -49,0% | |
| 2025-09-02 | WENDER JOSEPH H | Director | Open Market Sale | -11,200 | 55.04 | -616,432.32 | -59,9% | |
| 2025-09-02 | WENDER JOSEPH H | Director | Open Market Sale | -5,600 | 57.53 | -322,174.16 | -31,3% | |
| 2025-09-02 | Swayze Eric | Officer, EVP Research | Open Market Sale | -1,130 | 53.68 | -60,661.68 | -5,9% | |
| 2025-08-22 | Diaz Allene M. | Director | Open Market Sale | -1,427 | 42.53 | -60,687.17 | -5,9% | |
| 2025-08-18 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -10,000 | 43.98 | -439,776.00 | -42,7% | |
| 2025-08-06 | PARSHALL B LYNNE | Director | Open Market Sale | -4,600 | 41.87 | -192,595.10 | -18,7% | |
| 2025-08-06 | PARSHALL B LYNNE | Director | Open Market Sale | -400 | 42.63 | -17,051.00 | -1,7% | |
| 2025-08-05 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -10,000 | 42.86 | -428,593.00 | -41,7% | |
| 2025-08-04 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -9,549 | 42.80 | -408,701.02 | -39,7% | |
| 2025-07-30 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -2,432 | 45.00 | -109,440.00 | -10,6% | |
| 2025-07-11 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -1,160 | 41.74 | -48,416.20 | -4,7% | |
| 2025-05-01 | Hayden Michael R | Director | Open Market Purchase | 15,000 | 31.86 | 477,900.00 | +46,4% |
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-03-31 | 4.940 | 72,52 | 358.249 |
| 2026-03-26 | 1 | 72,70 | 73 |
| 2026-03-25 | 6.847 | 69,68 | 477.099 |
| 2026-03-23 | 5 | 70,99 | 355 |
| 2026-03-20 | 157 | 71,32 | 11.197 |
| 2026-03-19 | 30.432 | 71,67 | 2.181.061 |
| 2026-03-17 | 95 | 72,34 | 6.872 |
| 2026-03-13 | 755 | 72,34 | 54.617 |
| 2026-03-12 | 10.219 | 74,79 | 764.279 |
| 2026-03-11 | 1.337 | 75,66 | 101.157 |
| 2026-03-10 | 15.034 | 75,36 | 1.132.962 |
| 2026-03-04 | 71.539 | 78,66 | 5.627.258 |
| 2026-03-03 | 23.547 | 81,96 | 1.929.912 |
| 2026-02-25 | 34.535 | 85,45 | 2.951.016 |
| 2026-02-24 | 52.735 | 84,60 | 4.461.381 |
| 2026-02-23 | 19.581 | 83,15 | 1.628.160 |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| FMR LLC | 35,800,101 | 1,921,936,969 | 16.52 |
| Capital World Investors | 17,961,299 | 1,420,918,364 | 12.21 |
| VANGUARD GROUP INC | 16,440,459 | 1,300,604,712 | 11.18 |
| BlackRock, Inc. | 35,954,863 | 880,813,813 | 7.57 |
| WELLINGTON MANAGEMENT GROUP LLP | 24,753,325 | 524,650,318 | 4.51 |
| STATE STREET CORP | 29,469,865 | 352,034,127 | 3.03 |
| TWO SIGMA INVESTMENTS, LP | 52,908,646 | 285,771,560 | 2.46 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,148,849 | 249,157,703 | 2.14 |
| Tweedy, Browne Co LLC | 2,464,930 | 195,000,612 | 1.68 |
| JPMORGAN CHASE & CO | 3,415,792 | 184,098,769 | 1.58 |
| CITADEL ADVISORS LLC | 2,313,036 | 182,984,278 | 1.57 |
| VOYA INVESTMENT MANAGEMENT LLC | 95,958,760 | 158,488,868 | 1.36 |
| BAKER BROS. ADVISORS LP | 1,791,841 | 141,752,542 | 1.22 |
| Deep Track Capital, LP | 1,700,000 | 134,487,000 | 1.16 |
| AMERICAN CENTURY COMPANIES INC | 1,617,106 | 127,929,439 | 1.10 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,541,841 | 121,975,042 | 1.05 |
| CAPSTONE INVESTMENT ADVISORS, LLC | 84,949,000 | 116,698,689 | 1.00 |
| Pictet Asset Management Holding SA | 1,418,491 | 112,476,314 | 0.97 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,388,567 | 109,849,535 | 0.94 |
| ROYAL BANK OF CANADA | 7,879,997 | 104,814,000 | 0.90 |